Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results
The clinical outcome of autologous adipose stem cell (ASC) treatment of patients with multiple sclerosis (MS) was investigated following one year of observation. Methods. The clinical and MRI outcomes of 16 ASC-treated patients with RRMS and SPMS are reported after a one-year follow-up period. Resul...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/5302120 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553626251296768 |
|---|---|
| author | Adam Stepien Natalia L. Dabrowska Marzena Maciagowska Renata Piusinska Macoch Aleksandra Zolocinska Slawomir Mazur Katarzyna Siennicka Emilia Frankowska Rafał Kidzinski Małgorzata Chalimoniuk Zygmunt Pojda |
| author_facet | Adam Stepien Natalia L. Dabrowska Marzena Maciagowska Renata Piusinska Macoch Aleksandra Zolocinska Slawomir Mazur Katarzyna Siennicka Emilia Frankowska Rafał Kidzinski Małgorzata Chalimoniuk Zygmunt Pojda |
| author_sort | Adam Stepien |
| collection | DOAJ |
| description | The clinical outcome of autologous adipose stem cell (ASC) treatment of patients with multiple sclerosis (MS) was investigated following one year of observation. Methods. The clinical and MRI outcomes of 16 ASC-treated patients with RRMS and SPMS are reported after a one-year follow-up period. Results. At 18 months of follow-up, some patients showed “enticing” improvements on some exploratory efficacy measures, although a significant benefit was not observed for any measure across the entire group. Neither the progression of disability nor relapses were observed in any cases. In four patients, we found new gadolinium+ (Gd+) lesions on MRI. Our results indicate that ASC therapy is safe and does not produce any substantial side effects. Disease progression-free survival (PFS) of 18 months was seen in all patients with RRMS and SPMS. In these patients, EDSS scores did not progress above baseline scores. Gd-enhancing lesions were observed in two cases with RRMS, but these patients did not exhibit changes in EDSS score. Conclusion. Intrathecal treatment with ASCs is an attractive form of therapy for patients with MS but should be reserved for cases with aggressive disease progression, for cases that are still in the inflammatory phase, and for the malignant form. |
| format | Article |
| id | doaj-art-ab99a699ba6745558f24527728a59c04 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-ab99a699ba6745558f24527728a59c042025-02-03T05:53:37ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/53021205302120Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary ResultsAdam Stepien0Natalia L. Dabrowska1Marzena Maciagowska2Renata Piusinska Macoch3Aleksandra Zolocinska4Slawomir Mazur5Katarzyna Siennicka6Emilia Frankowska7Rafał Kidzinski8Małgorzata Chalimoniuk9Zygmunt Pojda10Department of Neurology, Military Institute of Medicine, Warsaw, PolandDepartment of Neurology, Military Institute of Medicine, Warsaw, PolandDepartment of Neurology, Military Institute of Medicine, Warsaw, PolandDepartment of Neurology, Military Institute of Medicine, Warsaw, PolandLaboratory of Cellular Engineering, M. Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, PolandDepartment of Breast Cancer and Reconstructive Surgery, Oncology Center-Institute, Warsaw, PolandLaboratory of Cellular Engineering, M. Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, PolandDepartment of Radiology, Military Institute of Medicine, Warsaw, PolandDepartment of Radiology, Military Institute of Medicine, Warsaw, PolandPolish Academy of Sciences, Warsaw, PolandLaboratory of Cellular Engineering, M. Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, PolandThe clinical outcome of autologous adipose stem cell (ASC) treatment of patients with multiple sclerosis (MS) was investigated following one year of observation. Methods. The clinical and MRI outcomes of 16 ASC-treated patients with RRMS and SPMS are reported after a one-year follow-up period. Results. At 18 months of follow-up, some patients showed “enticing” improvements on some exploratory efficacy measures, although a significant benefit was not observed for any measure across the entire group. Neither the progression of disability nor relapses were observed in any cases. In four patients, we found new gadolinium+ (Gd+) lesions on MRI. Our results indicate that ASC therapy is safe and does not produce any substantial side effects. Disease progression-free survival (PFS) of 18 months was seen in all patients with RRMS and SPMS. In these patients, EDSS scores did not progress above baseline scores. Gd-enhancing lesions were observed in two cases with RRMS, but these patients did not exhibit changes in EDSS score. Conclusion. Intrathecal treatment with ASCs is an attractive form of therapy for patients with MS but should be reserved for cases with aggressive disease progression, for cases that are still in the inflammatory phase, and for the malignant form.http://dx.doi.org/10.1155/2016/5302120 |
| spellingShingle | Adam Stepien Natalia L. Dabrowska Marzena Maciagowska Renata Piusinska Macoch Aleksandra Zolocinska Slawomir Mazur Katarzyna Siennicka Emilia Frankowska Rafał Kidzinski Małgorzata Chalimoniuk Zygmunt Pojda Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results Mediators of Inflammation |
| title | Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results |
| title_full | Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results |
| title_fullStr | Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results |
| title_full_unstemmed | Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results |
| title_short | Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results |
| title_sort | clinical application of autologous adipose stem cells in patients with multiple sclerosis preliminary results |
| url | http://dx.doi.org/10.1155/2016/5302120 |
| work_keys_str_mv | AT adamstepien clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults AT natalialdabrowska clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults AT marzenamaciagowska clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults AT renatapiusinskamacoch clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults AT aleksandrazolocinska clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults AT slawomirmazur clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults AT katarzynasiennicka clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults AT emiliafrankowska clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults AT rafałkidzinski clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults AT małgorzatachalimoniuk clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults AT zygmuntpojda clinicalapplicationofautologousadiposestemcellsinpatientswithmultiplesclerosispreliminaryresults |